Route 66 Endometrial Cancer SPORE

66 号公路子宫内膜癌孢子

• 批准号: 10711634
• 负责人: DORIS Mangiaracina BENBROOK
• 金额: $ 238.47万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-23 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10711634
• 关键词: Address; Affect; Aftercare; Atypical Endometrial Hyperplasias; Bioinformatics; Biological; Biological Markers; Biological Process; Biometry; Biopsy; Body Weight decreased; Cancer Biology; Cancer Model; Cancer Patient; Cancer Science; Clinical; Clinical Trials; Collaborations; Combination Drug Therapy; Communities; Complement; Data; Data Analyses; Death Rate; Dedications; Development; Disease; Drug Kinetics; Early Diagnosis; Endometrial Carcinoma; Endometrial Hyperplasia; Enrollment; Ensure; Equity; Fertility; Fostering; Funding; Future; Genes; Goals; Health Sciences; Heat shock proteins; Histology; Immunohistochemistry; Immunologics; Incidence; Individual; Institution; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of ovary; Marriage; Measures; Mentors; Metabolic; Minority; Molecular; Molecular Chaperones; Mutation; New Mexico; Obesity; Oklahoma; Pathologic; Pathology; Patient-Focused Outcomes; Patients; Population Sciences; Premenopause; Prevention; Prevention strategy; Primary Prevention; Progestins; Proteins; Recurrence; Research; Research Personnel; Research Priority; Research Project Grants; Research Support; Resources; Route; Scientist; Specialized Program of Research Excellence; Specimen; Standardization; TP53 gene; Testing; Therapeutic; Translational Research; Tumor Biology; Underrepresented Minority; Underrepresented Populations; United States; Universities; Uterus; Washington; Woman; Work; angiogenesis; anticancer research; axl receptor tyrosine kinase; behavior test; biobank; cancer therapy; career; clinical practice; design; drug development; early phase clinical trial; effective therapy; fluorescence imaging; forging; improved; inhibitor; innovation; interest; member; metabolomics; molecular marker; novel; novel drug combination; novel marker; novel strategies; novel therapeutics; pre-clinical; preservation; prevent; programs; recruit; response; response biomarker; stable isotope; therapy outcome; translational research program; translational study; treatment response; treatment strategy; virtual

PROJECT SUMMARY The Route 66 Endometrial Cancer SPORE brings together interactive research teams from three institutions to create a dynamic translational research program aimed at developing and testing new strategies to prevent and treat endometrial cancer. This SPORE includes three research projects; an administrative core; a biostatistics and bioinformatics core; a biospecimens, metabolomics, and pathology core; and developmental research and career enhancement programs. The three projects, chosen and refined with extensive input from our internal and external advisory boards, are designed to have significant potential to change clinical practice within five years. Project 1: HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy. Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer. Project 3: Improving Primary Prevention and Uterine Preservation in Premenopausal Women with Obesity and Endometrial Hyperplasia. Projects 1 and 2 are clinical/translational projects, whereas Project 3 is an early detection, prevention, or population science project. All three projects include clinical trials and represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University in St. Louis and our collaborators at the University of New Mexico and the University of Oklahoma Health Sciences Center. The overall aims of our SPORE are to 1) Test promising new therapies to treat or prevent endometrial cancer; 2) Elucidate the key biologic processes that drive endometrial cancer and develop novel biomarkers to predict development of endometrial cancer and response to therapies; 3) Leverage and enhance capacities of shared research resources; 4) Recruit and mentor new investigators and support innovative ideas in translational endometrial cancer research; 5) Facilitate collaboration of those interested in endometrial cancer research; and 6) Ensure equitable enrollment in clinical trials and involvement of diverse community members and investigators in research. In completing the work proposed here, we will test three new strategies to prevent or treat endometrial cancer. Future work can be directed at moving the most promising treatment approaches into larger trials. Additionally, we will obtain an unprecedented level of molecular, cellular, immunologic, and metabolomic detail regarding endometrial cancer and response to treatment, which will likely lead to development of additional novel clinical trials. Finally, by developing new ideas, investigators, and collaborations, we will expand the breadth and depth of research aimed at treating or preventing endometrial cancer.

项目概要 Route 66 子宫内膜癌 SPORE 汇集了来自三个机构的互动研究团队， 创建一个动态的转化研究计划，旨在开发和测试新的策略来预防 并治疗子宫内膜癌。该 SPORE 包括三个研究项目；行政核心；一个 生物统计学和生物信息学核心；生物样本、代谢组学和病理学核心；和发育的 研究和职业提升计划。这三个项目是在广泛的投入下选择和完善的 我们的内部和外部顾问委员会旨在具有改变临床实践的巨大潜力 五年内。项目 1：HSPA 蛋白在晚期和复发性子宫内膜癌治疗中的应用。项目2： 抑制 AXL 以改善子宫内膜癌的治疗反应。项目 3：改善小学 绝经前妇女肥胖和子宫内膜增生的预防和子宫保存。 项目 1 和 2 是临床/转化项目，而项目 3 是早期检测、预防或治疗 人口科学项目。所有三个项目都包括临床试验并代表精心选择的婚姻 选定的子宫内膜癌研究重点与圣路易斯华盛顿大学的优势之间的关系 路易斯和我们在新墨西哥大学和俄克拉荷马健康科学大学的合作者 中心。我们 SPORE 的总体目标是 1) 测试有前景的治疗或预防子宫内膜异位症的新疗法 癌症; 2) 阐明导致子宫内膜癌的关键生物学过程并开发新的生物标志物 预测子宫内膜癌的发展和对治疗的反应； 3）利用和增强能力 共享研究资源； 4）招募和指导新的研究人员并支持创新想法 转化子宫内膜癌研究； 5) 促进对子宫内膜癌感兴趣的人的合作 研究; 6) 确保临床试验的公平招募和不同社区成员的参与 和研究人员。在完成此处提出的工作时，我们将测试三种新策略 预防或治疗子宫内膜癌。未来的工作可以针对最有希望的治疗方法 进入更大规模的试验。此外，我们将获得前所未有的分子、细胞、 有关子宫内膜癌和治疗反应的免疫学和代谢组学细节，这可能会 导致更多新颖的临床试验的发展。最后，通过提出新的想法、研究人员和 通过合作，我们将扩大旨在治疗或预防子宫内膜异位症的研究的广度和深度 癌症。